Creatinine, with Estimated eGFR, Serum
Creatinine is a metabolic end product (waste) produced endogenously from creatine and creatine phosphate as a result of the metabolic processes of muscle. Most of the body’s creatine is found in muscle tissue where it is present as creatine phosphate and serves as a high energy storage reservoir for conversion to adenosine triphosphate. Once creatinine is created as waste, it is carried by the circulatory system to the kidneys and is excreted by filtration through the glomerulus and by tubular secretion. Creatinine assays are conducted for diagnostic purposes of kidney function, for therapeutic monitoring of acute and chronic renal diseases, and for monitoring kidney dialysis. Serum creatinine and urea levels are elevated in patients with renal malfunction, especially in patients with decreased glomerular filtration. In the early stages of kidney damage, the rise in the serum urea level usually precedes the increase in serum creatinine; however, serum urea level is affected by factors such as diet, degree of hydration, and protein metabolism. Serum creatinine level, however, tends to be constant and unaffected by similar variables, making serum creatinine a significantly more reliable renal function screening test than serum urea. The estimated glomerular filtration range (eGFR) is a calculated value that can be derived from patient variables like sex and weight and the serum creatinine value to give additional information to the clinician regarding patient kidney status.
- Renal function evaluation (providing rough approximation of glomerular filtration)
- To estimate glomerular filtration rate (eGFR)
- Monitor patients on hemodialysis
- As an aid in diagnosis of muscular dystrophies and other muscle wasting disorders
- As an aid in diagnosis of rhabdomyolysis
Increased in:
- Renal diseases and insufficiency with decreased glomerular filtration rate
- Acute or chronic renal failure
- Urinary tract obstruction
- Reduced renal blood flow including congestive heart failure
- Shock and dehydration
- Rhabdomyolysis
- Hypothyroidism and diabetes
- Increased in patients taking nephrotoxic drugs
Decreased in:
- Reduced muscle mass
- Advanced liver disease
- Inadequate protein intake
- Pregnancy
- Early Diabetes mellitus
| Age | / Sex |
mg/dL | umol/L |
| 18-60yr | Male | 0.9-1.3 | 80-155 |
| Female | 0.6-1.1 | 53-97 | |
| 60-90yr | Male | 0.8-1.3 | 71-155 |
| Female | 0.6-1.2 | 53-106 | |
| >90 | Male | 1.0-1.7 | 88-150 |
| Female | 0.6-1.3 | 53-115 |
Serum (SST) or Plasma Fluoride (Grey) or Heparin (Green).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- J Nephrol. 2010 Mar-Apr;23(2):125-32. [PMID: 20213606]
- Curr Opin Nephrol Hypertens. 2005 Nov;14(6):567-72. [PMID: 16205477]
- Am Fam Physician. 2004;70:1091. [PMID: 15456118]
- Am Fam Physician. 2005;72:1723. [PMID: 16300034]
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757